Care
The clinical engine — assessment, scoring, and monitoring that clinicians use directly.
Mental and brain illness are complex.
Symptoms overlap across conditions.
Polygenic and highly downstream.
Shaped by socio-economic environment.
So assessment must be dynamic —
built on multiple data streams,
continuously adapting as symptoms change.
We need it all — at one point.
That's why we built LifeBack.
Translating precision in mental healthcare.
Connected intelligence for brain and mental healthcare.
SIPL unifies clinical care, behavioural signals, neuroscience, genomics, and discovery into a single responsible, explainable AI infrastructure that keeps learning from new data, adapts across new populations, and brings multiple signals together into one picture.
GrantedIndian patent, PCT filed
91%HAM-D agreement, details
500+Hospital assessments
GCE-III₹50L+ equity-free fund support (BIRAC, DBT, BMGF)
Multi-siteClinical & institutional pilot partnerships
DPIITRecognised deep-tech startup
2018DBT–MoST Most Innovative Startup Award
About SIPL
Deep research, translated into clinical-grade AI.
Sequoia Insilico Pvt. Ltd. is a deep-science BioAI company in New Delhi. Our work is grounded in research across bioinformatics, systems biology, and computational psychiatry.
Each finding follows one path: researched, validated in hospital cohorts, and deployed as a clinical-grade model. LifeBack™ is the first platform built this way. Our long-term aim is to redefine psychiatric diagnosis through a population-scale atlas of phenotypes, biotypes, and treatment outcomes.
The SIPL architecture
One loop, not three tools.
Care is delivered, integrated into hospital workflow, and continuously improved by discovery — one connected system.
Integration
Care built into hospital workflows and records, so it runs inside existing practice, not alongside it.
Discovery
New findings — from our R&D, patient-reported outcomes, and outside research — validated and folded back into care.
A closed loop, not a pipelineEvery stage feeds the next — the last feeds back into the first.
1
IntegrateBring in permitted data
2
AssessScore clinical patterns
3
StratifyGroup by risk, response
4
GuideInform the clinician
5
MonitorTrack change over time
6
DiscoverFeed the next study
Continuous, automated learning feedback
Science
Every model earns its place in care.
We treat each model and biomarker as a hypothesis to test, and we report results with their limitations.
How we validate
Clinically grounded and multimodal by design.
91%
agreement with clinician-rated HAM-D across 500+ assessments, in a clinical validation collaboration with ABVIMS and Dr. RML Hospital, New Delhi.
- Literature grounding
- Ethics review
- Data quality
- Model evaluation
- External validation
Publications, conferences, and accolades
Publications
- [Author et al. Title. Journal, Year.]
- [Author et al. Title. Journal, Year.]
Conferences
- [Conference name, City, Year: talk or poster title]
Accolades
- Equity-free Grand Challenges India (GCE-III) award — ₹50L+ fund support — from BIRAC, DBT, and the Bill & Melinda Gates Foundation
- Indian Patent No. 202511025669 — published; WIPO PCT application under process
- DPIIT-recognised deep-science startup
BioAI for biopharma
Brain-health intelligence for drug development.
We apply our multimodal models and phenotypes to help biopharma design better psychiatric trials and understand treatment response.
Patient stratification
Identify likely responders using behavioural, clinical, and genomic signals.
Digital biomarkers
Objective, repeatable measures of symptom change from voice and facial behaviour.
Pharmacogenomics In pipeline
Genetic markers of drug response and tolerability, linked to clinical context.
Real-world evidence
Longitudinal outcomes from governed, consented clinical data.
Engagement: Data-as-a-Service (DaaS), co-designed studies
Discuss a research objective
Our precision framework
Precision care must be multidimensional.
At the point of care, precision is ultimately delivered to the individual patient. But true individual precision depends on two equally important foundations.
Diagnostic precision
Understanding overlapping disorders, comorbidities, differential diagnoses, and disease trajectories accurately — rather than treating conditions as isolated labels.
Population precision
Ensuring models are relevant to the demographic, genetic, linguistic, cultural, and socioeconomic diversity of the population in which they are used.
LifeBack™ brings these dimensions together — so population-relevant, diagnostically precise intelligence can be translated into truly individualised care.
LifeBack™ platform
Built to deploy anywhere, engineered for India first.
LifeBack™ is SIPL’s flagship clinical-grade platform for brain and mental health — requiring clinical intervention, not a self-serve consumer app — designed for B2B and B2B2C deployment with white-label integration for hospitals, healthcare providers, corporates, and institutions. Built with leading hospitals and clinical KOLs (Key Opinion Leaders), it combines demographically validated deep learning models with rigorous patient-centred clinical research and a strong translational science foundation.
Built for diversity, adaptable globally
A use-case–specific small language model for India's diverse, heterogeneous population — adaptable globally. SaaS, API-first: pilot in weeks with no IT change; production-ready, integrating into existing HIS/EMR.
Across the patient journey
Clinical workflows, multimodal data, and biological insights follow the patient across risk, diagnosis, response, prognosis, remission, and relapse — with adaptive evaluation, clinician-led planning, and long-term surveillance. A patient app links PROs to clinician dashboards between visits, extending post-remission and relapse analytics to patients, not just clinicians.
A collaboration platform
Backed by strong R&D and translational research, SIPL partners with hospitals, research institutions, and biopharma across brain health, mental health, and precision medicine — through co-creation, joint publications, co-hosted conferences, and patent partnerships, licensing complementary IP to strengthen services like Data-as-a-Service (DaaS).
Let's build the future of brain and mental healthcare together.
Tell us your focus — hospital, research, genomics, biopharma, or investment — and we’ll connect you with the right team.
← Back to home
About SIPL
The people behind SIPL.
Scientists, engineers, and clinicians working together to make brain and mental health measurable. Our work is grounded in research across bioinformatics, systems biology, and computational psychiatry.
Founders and team
The scientists who lead SIPL's research, engineering, and company building.
Dr. Anupama Singh
Founder and CEOLeads SIPL's scientific direction and the LifeBack™ platform, with a focus on psychiatric genomics and precision psychiatry.
- PhD, Bioinformatics and Systems Biology, JNU
- CSIR-JRF
- National Talent Scholar
Dr. Harsh Bhasin
Co-founder, ML and AI LeadLeads the machine learning and AI work behind SIPL's clinical-grade models.
- PhD, JNU
- Visvesvaraya Fellow
- ~40 publications
Clinical collaborators
Clinicians and scientists who help design, validate, and test our models in real hospital and laboratory settings.
Prof. R.P. Beniwal
ABVIMS and Dr. RML Hospital, New DelhiClinical collaborator on the LifeBack™ validation study at ABVIMS and Dr. RML Hospital.
- [Department / title]
Dr. Vishal Deshwal
[Institution]Clinical collaborator on LifeBack™.
- [Department / title]
Dr. Qurratulain Hasan
SAAZ Genetics, HyderabadClinical genomics collaborator, supporting SIPL's genomics and pharmacogenomics work.
- [Title]
Advisors
Experts who guide our science, clinical strategy, and growth.
[Advisor name]
[Area, e.g. Scientific advisor][One line on their expertise and how they advise SIPL.]
[Advisor name]
[Area, e.g. Clinical advisor][One line on their expertise and how they advise SIPL.]
[Advisor name]
[Area, e.g. Business advisor][One line on their expertise and how they advise SIPL.]
Work with us.
We welcome researchers, engineers, and clinicians who want to bring precision to psychiatry.
← Back to home
Investors and strategic partners
A specialised BioAI platform connecting care and discovery.
SIPL builds clinical-grade AI for brain and mental healthcare. Each validated model serves patients today and creates evidence for the next discovery.
GrantedIndian patent, PCT filed
91%HAM-D agreement
500+Hospital assessments
GCE-III₹50L+ fund support
Why SIPL
Four reasons the platform can compound in value over time.
Domain depth
A specialised focus on brain and mental health, grounded in the team's own research.
Multimodal context
Clinical, behavioural, biological, and longitudinal data in one record.
Ecosystem reach
B2B licensing, white-label deployment, and KOL co-branded programmes across care, research, and biopharma.
Responsible scale
Human oversight, validation, and transparent limitations built in from the start.
What is already in place
The protection, validation, and funding behind the platform.
| Intellectual property | Indian Patent No. 202511025669 — published (granted); corresponding WIPO PCT application under process. |
|---|---|
| Clinical validation | Clinical validation collaboration with ABVIMS and Dr. RML Hospital, New Delhi: 91% agreement with clinician-rated HAM-D across 500+ assessments. [Add metric type and sample size.] |
| Fund support | Equity-free Grand Challenges India (GCE-III) award — ₹50L+ — supported by BIRAC, DBT, and the Bill & Melinda Gates Foundation. Combined with founder bootstrapping, total investment in the company to date is ₹90L+, with no equity diluted. |
| Recognition | DPIIT-recognised deep-science MedTech startup. |
| Interoperability | Designed for the Indian health stack, with FHIR R4 support in development. |
Pipeline
Each line follows the same path: researched, validated, then deployed as a clinical-grade model.
- LifeBack™ depression assessmentMultimodal assessment from voice, facial behaviour, and structured clinical interview. Ready for multi-location pilots.Validated, pilot-ready
- Longitudinal monitoringTracking change in severity and treatment response over time.In development
- Genomics and pharmacogenomics moduleGenetic markers of drug response and tolerability, linked to clinical context.In pipeline
- Neurocircuit biotype atlasBrain-circuit subtypes of depression to guide stratification and treatment.Research
Long-term aim
To redefine psychiatric diagnosis through a population-scale atlas of phenotypes, biotypes, and treatment outcomes. Every assessment adds to the evidence that improves the next.
Request investor access.
Our seed round is active. Contact us for the investor deck, financial model, and data-room access.
← Back to investor overview
Investors
Request investor access.
We share our full investor materials with investors and strategic partners on request. Email us with a few details and we will send you what you need.
What you will receive
The investor pack gives you the full picture behind the public overview.
Investor deck
Problem, platform, market, business model, team, and use of funds.
Financial model
Revenue assumptions, cost structure, and funding requirements.
Validation summary
Study design, metrics, and results from the ABVIMS and Dr. RML Hospital collaboration.
IP and funding documents
Patent grant, PCT filing, and the equity-free GCE-III award details.
Data room access
Company, legal, and compliance documents, shared after a non-disclosure agreement where needed.
Founder call
A conversation with the founders to discuss your questions and fit.
What to include in your email
These details help us send the right materials and respond quickly.
- Name and organisationYour role and the fund or company you represent
- Investor typeAngel, VC, family office, corporate, or strategic
- Stage and cheque sizeYour usual investment stage and range
- Areas of interestFor example clinical AI, genomics, or biopharma
- TimelineWhen you are looking to make decisions
- How you found usReferral, event, or online
Send your request to
Subject line: Investor access request - SIPL
What to expect
A simple process from first email to full access.
- 1. You email usSend your request with the details above.Day 0
- 2. We replyWe confirm receipt and share the investor deck.[Within 3 working days]
- 3. NDA, if neededWe sign a non-disclosure agreement before sharing confidential documents.As needed
- 4. Data room and modelYou receive the financial model and data room access.After NDA
- 5. Founder callWe meet to answer your questions and discuss next steps.Scheduled together
← Back to home
Partners
Where SIPL creates value.
SIPL is designed to work across brain and mental healthcare — from hospitals and clinicians to research institutions, biopharma, genomics labs, and channel and implementation partners. Each segment below shows the value we offer and how we engage.
Hospitals and health systems
Standardised psychiatric assessment and outcome tracking within existing clinical workflows.
Engagement: multi-location pilot, platform licenceClinicians and clinics
Faster structured assessment and a longitudinal view of each patient.
Engagement: subscription accessResearch institutions
Governed multimodal data and study infrastructure for mental-health research.
Engagement: research collaboration, co-funded studiesBiopharma and CROs
Patient stratification, digital biomarkers, and real-world evidence for trials.
See BioAI for biopharmaGenomics and diagnostics labs
Pharmacogenomic and genomic results linked to clinical and longitudinal context.
Engagement: integration and co-developmentChannel and implementation partners
Probable institutions and distribution partners who could bring LifeBack™ to their networks — not existing clients, but where we scope future value.
Engagement: white-label, reseller, implementation partnershipHow we work with partners
- B2B platform licensingLifeBack™ licensed to hospitals, clinic networks, and health systems.
- White-label deploymentThe platform delivered under a partner's own brand, with SIPL running the models behind it.
- Co-branding with KOL partnersClinical programmes developed and co-branded with leading psychiatrists and institutions.
Current partners and collaborators
Named relationships already in place — distinct from the probable-partner categories above.
- RML Hospital, New DelhiResearch collaborator — clinical validation of LifeBack™ (see Science).Active
- Jahangir HospitalImplementation partner for LifeBack™ deployment.In progress
- St John's Medical College, BengaluruResearch collaborator and co-applicant on a BIRAC grant application.Research
← Back to home
Trust
Responsible by design.
AI supports the professional; the professional leads the care. Safeguards are built into the platform, not added later.
Research ethos
- Hypothesis-drivenTestable question first
- Ethics approvalICMR guidelines
- Human oversightClinician-accountable care
- Transparent limitsLimitations disclosed
Platform safeguards
- Consent and purposeClear use permissions
- Role-based accessAuthorised users only
- AuditabilityTraceable actions & versions
- Data protectionDPDPA, 2023
Regulatory pathway
- SaMD frameworkCDSCO device framework
- Full lifecycle validationClinical + post-market
- Cybersecurity & privacyRisk managed lifecycle
- Clinician-in-the-loopClinician holds authority
← Back to home
Contact
Let's talk.
Hospital, research, genomics, biopharma, investment, or a media enquiry — tell us your objective and we'll route you to the right person; we read every message and reply from New Delhi.
Reach us directly
General & partnerships
General and partnership enquiries
Hospitals, clinicians, research institutions, biopharma, and channel partners.
contact@sequoiainsilico.com Email usInvestors
Investors and strategic partners
Our seed round is active. Request the investor deck, financial model, and data-room access.
Request investor access
← Back to home
Careers
Join us.
We're a small, research-led team building clinical-grade AI for brain and mental health — open roles and standing searches across our clinical and research side.
What we're searching for
Medical board and referral board
Experienced clinical psychologists, psychiatrists, and neurologists with 15+ years of experience.
Get in touch